secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001493152-25-001314
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma reports favorable Phase 1 safety/tolerability for oral antiviral CDI-988 at 800 mg for 10 days
--------------------------------------------------------------------------------

- Phase 1 MAD study shows CDI-988 well-tolerated up to 800 mg/day for 10 days; new cohort at 1,200 mg for 5 days planned.
- Pan-viral inhibitor targets norovirus and coronaviruses; no approved antivirals for norovirus exist.
- Company plans to start human challenge study in norovirus-infected subjects later in 2025.
- Norovirus outbreaks surge in U.S.; CDC estimates 21 million annual U.S. cases and $10.6B economic burden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225001314/0001493152-25-001314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225001314/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer